{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:38:43Z","timestamp":1791855523166,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s10157-019-01754-1","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T08:02:46Z","timestamp":1560240166000},"page":"1154-1160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Assessment of factors associated with mizoribine responsiveness in children with steroid-dependent nephrotic syndrome"],"prefix":"10.1007","volume":"23","author":[{"given":"Tomomi","family":"Kondoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6460-1188","authenticated-orcid":false,"given":"Yohei","family":"Ikezumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naonori","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsushi","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,11]]},"reference":[{"issue":"10141","key":"1754_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018;392(10141):61\u201374.","journal-title":"Lancet"},{"key":"1754_CR2","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/archdischild-2015-308924","volume":"101","author":"N Larkins","year":"2016","unstructured":"Larkins N, Kim S, Craig J, Hodson E. Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children. Arch Dis Child. 2016;101:404\u20138.","journal-title":"Arch Dis Child."},{"issue":"9950","key":"1754_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, et al. Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384(9950):1273\u201381.","journal-title":"Lancet"},{"key":"1754_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00467-010-1707-7","volume":"26","author":"S Fujinaga","year":"2011","unstructured":"Fujinaga S, Hirano D, Nishizaki N, Someya T, Ohtomo Y, Ohtsuka Y, et al. Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration. Pediatr Nephrol. 2011;26:479\u201383.","journal-title":"Pediatr Nephrol."},{"key":"1754_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s00467-004-1647-1","volume":"20","author":"Y Kawasaki","year":"2005","unstructured":"Kawasaki Y, Suzuki J, Takahashi A, Isome M, Nozawa R, Suzuki H. Mizoribine oral pulse therapy for steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2005;20:96\u20138.","journal-title":"Pediatr Nephrol."},{"key":"1754_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1046\/j.1523-1755.2000.00168.x","volume":"58","author":"K Yoshioka","year":"2000","unstructured":"Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int. 2000;58:317\u201324.","journal-title":"Kidney Int."},{"key":"1754_CR7","doi-asserted-by":"publisher","first-page":"681482","DOI":"10.1155\/2009\/681482","volume":"2009","author":"Y Kawasaki","year":"2009","unstructured":"Kawasaki Y. Mizoribine: a new approach in the treatment of renal disease. Clin Dev Immunol. 2009;2009:681482.","journal-title":"Clin Dev Immunol."},{"key":"1754_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1046\/j.1328-8067.2001.01533.x","volume":"44","author":"M Honda","year":"2002","unstructured":"Honda M. Nephrotic syndrome and mizoribine in children. Pediatr Int. 2002;44:210\u20136.","journal-title":"Pediatr Int."},{"key":"1754_CR9","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s10157-013-0856-y","volume":"18","author":"O Uemura","year":"2014","unstructured":"Uemura O, Nagai T, Ishikura K, Ito S, Hataya H, Gotoh Y, et al. Creatinine-based equations to estimate glomerular filtration rate in Japanese children and adolescents with chronic kidney disease. Clin Exp Nephrol. 2014;18:626\u201333.","journal-title":"Clin Exp Nephrol."},{"key":"1754_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/S0378-4347(00)80663-5","volume":"432","author":"H Hosotsubo","year":"1988","unstructured":"Hosotsubo H, Takahara S, Taenaka N. Simplified high-performance liquid chromatographic method for determination of mizoribine in human serum. J Chromatogr. 1988;432:340\u20135.","journal-title":"J Chromatogr."},{"key":"1754_CR11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2174\/092986730607220401123549","volume":"6","author":"H Ishikawa","year":"1999","unstructured":"Ishikawa H. Mizoribine and mycophenolate mofetil. Curr Med Chem. 1999;6:575\u201397.","journal-title":"Curr Med Chem."},{"key":"1754_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1365-2125.2006.02779.x","volume":"63","author":"D Stypinski","year":"2007","unstructured":"Stypinski D, Obaidi M, Combs M, Weber M, Stewart AJ, Ishikawa H. Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Br J Clin Pharmacol. 2007;63:459\u201368.","journal-title":"Br J Clin Pharmacol."},{"key":"1754_CR13","first-page":"3643","volume":"28","author":"K Sonda","year":"1996","unstructured":"Sonda K, Takahashi K, Tanabe K, Funchinoue S, Hayasaka Y, Kawaguchi H, et al. Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transpl Proc. 1996;28:3643\u20138.","journal-title":"Transpl Proc."},{"key":"1754_CR14","first-page":"40","volume":"78","author":"M Fujieda","year":"2012","unstructured":"Fujieda M, Ishihara M, Morita T, Hayashi A, Okada S, Ohta T, et al. Effect of single-dose oral mizoribine pulse therapy twice per week for frequently relapsing steroid-dependent nephrotic syndrome. Clin Nephrol. 2012;78:40\u20136.","journal-title":"Clin Nephrol."},{"key":"1754_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.5414\/CNP69179","volume":"69","author":"M Fujieda","year":"2008","unstructured":"Fujieda M, Ishihara M, Morita T, Hayashi A, Utsunomiya Y, Ohta T, et al. Effect of oral mizoribine pulse therapy for frequently relapsing steroid-dependent nephrotic syndrome. Clin Nephrol. 2008;69:179\u201384.","journal-title":"Clin Nephrol."},{"key":"1754_CR16","first-page":"52","volume":"20","author":"Y Kawasaki","year":"2007","unstructured":"Kawasaki Y, Takano K, Isome M, Suzuki J, Suyama K, Kanno H, et al. Efficacy of single dose of oral mizoribine pulse therapy two times per week for frequently relapsing nephrotic syndrome. J Nephrol. 2007;20:52\u20136.","journal-title":"J Nephrol."},{"key":"1754_CR17","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1007\/s00467-005-2025-3","volume":"20","author":"Y Ohtomo","year":"2005","unstructured":"Ohtomo Y, Fujinaga S, Takada M, Murakami H, Akashi S, Shimizu T, et al. High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity. Pediatr Nephrol. 2005;20:1744\u20139.","journal-title":"Pediatr Nephrol."},{"key":"1754_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejphar.2008.02.043","volume":"586","author":"N Mori","year":"2008","unstructured":"Mori N, Yokooji T, Kamio Y, Murakami T. Characterization of intestinal absorption of mizoribine mediated by concentrative nucleoside transporters in rats. Eur J Pharmacol. 2008;586:52\u20138.","journal-title":"Eur J Pharmacol."},{"key":"1754_CR19","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2133\/dmpk.DMPK-11-NT-040","volume":"26","author":"M Fukao","year":"2011","unstructured":"Fukao M, Ishida K, Sakamoto T, Taguchi M, Matsukura H, Miyawaki T, Hashimoto Y. Effect of genetic polymorphisms of SLC28A1, ABCG2, and ABCC4 on bioavailability of mizoribine in healthy Japanese males. Drug Metab Pharmacokinet. 2011;26:538\u201343.","journal-title":"Drug Metab Pharmacokinet."},{"key":"1754_CR20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1124\/jpet.107.131482","volume":"324","author":"G Minuesa","year":"2008","unstructured":"Minuesa G, Purcet S, Erkizia I, Molina-Arcas M, Bofill M, Izquierdo-Useros N, et al. Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells. J Pharmacol Exp Ther. 2008;324:558\u201367.","journal-title":"J Pharmacol Exp Ther."},{"key":"1754_CR21","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1681\/ASN.2006070732","volume":"18","author":"A Nakajo","year":"2007","unstructured":"Nakajo A, Khoshnoodi J, Takenaka H, Hagiwara E, Watanabe T, Kawakami H, et al. Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance. J Am Soc Nephrol. 2007;18:2554\u201364.","journal-title":"J Am Soc Nephrol."}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01754-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-019-01754-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01754-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T08:06:49Z","timestamp":1663661209000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-019-01754-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,11]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1754"],"URL":"https:\/\/doi.org\/10.1007\/s10157-019-01754-1","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,11]]},"assertion":[{"value":"16 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted (IRB approval number HM18-119) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any animal studies performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}